US Equity Strategy: Monthly Strategy Guide - April
Transcription
US Equity Strategy: Monthly Strategy Guide - April
MORGAN STANLEY RESEARCH Adam S. Parker, Ph.D. US Equity Strategy The Market The Themes The Sector Bets The Portfolio Chief US Equity Strategist [email protected] +1 212 761-1755 www.morganstanley.com/equitystrategy Brian T. Hayes, Ph.D. [email protected] +1 212 761-7991 Antonio Ortega [email protected] +1 212 761-4783 Phillip Neuhart [email protected] +1 212 761-8584 Yaye Aida Ba [email protected] +1 212 761-6537 Allison Rabkin Golden [email protected] +1 212 761-3023 For stock ideas or to decompose individual names, visit: www.morganstanley.com/equitystrategy Morgan Stanley does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analyst certification and other important disclosures, refer to the Disclosure Section located at the end of this report. MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Outline • Part I: The Case for Expansion Until 2020 ……………………………….. 4 • Part II: The Multiple, Earnings, and Margins ...………………………….. 14 • Part III: Market Microstructure …………………………………………….. 21 • Part IV: Sector Bets ………………………………………………………... 45 • Part V: Arrows in the Quiver and the MOST Strategic Portfolio ………. 52 Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 2 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Four Charts You Can’t Miss Historically, multiple expansion occurs with higher real rates. Estimates have come down sharply for 2015. Annual S&P500 Consensus EPS As of April 2015 P/E Ratio vs. Real Long-Term Treasury Yield Since 1930 $140 20x 2016E 2015E $135 $135.61 18x $130 16x 2014E P/E Ratio $125 $119.72 2013 14x $120 12x 2012 $119.31 $115 10x $110.67 $110 8x $105 $103.21 $100 Jan-11 Jun-11 Nov-11 Apr-12 Sep-12 Feb-13 Jul-13 Dec-13May-14 Oct-14 Mar-15 6x 4x < 0% 0-1% 1-2% 2-3% 3-4% 4-5% 5-6% > 6% Real Long-Term Treasury Yield We are overweight Energy and Discretionary. Margin expansion potential differs by stock size. 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 16 Staples Industrials Energy (10%) Utilities E (5%) Overweights - Discretionary, Energy Market-Weights - Materials, Health Care, Financials, Telecoms, Technology Underweights - Utilities, Industrials, Staples Technology 0% Telecoms 5% Health Care Mega Small Materials Large Mid Morgan Stanley Sector Recommendations As of April 2015 Financials 10% Top 1500: Net Margins by Market Capitalization, Through 2016E Discretionary 15% 5% 4% 3% 2% 1% 0% (1%) (2%) (3%) (4%) (5%) (6%) Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 3 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Part I: The Case for Expansion Until 2020 • Economic Factors • Corporate Behaviors • Credit Cycle Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 4 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Key Economic Growth Indicators Expanding While Consumer Confidence Is Only Average Growth in Key Economic Indicators, % year-over-year Consumer Confidence Index 10% 160 140 5% 120 100 0% 80 (5%) 60 40 (10%) (15%) Jul-09 Jul-10 Industrial production Jobs Real retail sales Real income less transfers Jul-11 Jul-12 Jul-13 Jul-14 20 0 67 72 77 82 87 92 97 02 07 12 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 5 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Debt-to-Disposable Income Back Near Pre-Bubble Levels and Obligations Are Declining Ratio of Payments to After-Tax Income Ratio of Debt to Disposable Income 150% 18.5% 135% 18.0% 130% 17.5% 110% 108% 17.0% 16.5% 90% 16.0% 70% 15.5% 50% 1981 15.0% 1986 1992 1997 2003 2008 2014 82 86 90 94 98 02 06 10 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 6 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy 75% of Household Balance Sheets Is in Mortgages and the Effective Yield Has Fallen ($bn) Household Balance Sheet 16000 Effective Yield on All Outstanding Mortgages vs 30-Year Fixed-Rate Mortgage Rate 12% 30-year FRM Rate 14000 10% Home mortgages 12000 Effective Yield 8% 10000 Nonrevolving credit 6% 8000 Revolving credit 6000 4% 3.9% 4000 2% 2000 0% 0 82 86 90 94 98 02 06 10 14 90 94 98 02 06 10 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 7 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Delinquencies Are at Multi-Year Lows and Low Risk of Recession Currently Indicated Very Low Risk of Recession Currently Indicated by MSRISK Percent of Balance 90+ Days Delinquent by Type of Loan Recession 95% Threshold (lhs) 14% MSRISK (lhs) Volatility (rhs) 100% 12% 10% 500% 400% 75% 8% 300% 50% 6% 200% 4% Credit Card 25% 100% Mortgage 2% Total 0% 0% 04 05 06 07 08 09 10 11 12 13 14 0% 61 66 71 76 81 86 91 96 01 06 11 Source: ClariFi, Thomson Reuters, Morgan Stanley Research. Note: The level of MSRISK must pass the 95% confidence threshold to signal recession has begun. Volatility in the MSRISK must pass 300% to provide the 6-month lead-time for the start of recession. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 8 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Capital Spending Seems Constrained Top 1500 Capital Spending-to-Sales Through 2016E Y/Y Growth in Capital Spending As of Q4 2014 12% 20% 15% 10% 10% 5% 0% 8% 2015E 6.7% 2016E 6.3% 6% 2015E 4.6% (5%) 4% Technology Health Care Utilities Materials Energy Discretionary Top 1500 Telecom Staples Industrials (10%) 2% Capex-to-Sales ex Energy and Utilities Capex-to-Sales 2016E 4.4% 0% 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 16 Source: Haver, ClariFi, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 9 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Inventory-to-Sales Is Contained in the US; Further Labor Productivity Is Likely Top 1500 Inventory-to-Sales Through Q4 2014 13% Nonfarm Productivity: Quarterly Percent Change 4-Quarter Moving Average, Through Q4 2014 1.6% 1.4% 12% 1.2% 1.0% 11% 0.8% 0.6% 10% 0.4% 9% 0.2% 0.0% 8% (0.2%) 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 03 05 07 09 11 13 Source: Haver, ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 10 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Debt Maturities Have Been Pushed Out and Interest Coverage Ratios Are High S&P500 Loan Distribution by Year of Maturity ($Bn) 600.0 Top 1500 Interest Coverage Through Q4 2014 10x 9x 500.0 8x 7x 400.0 6x 300.0 5x 4x 200.0 3x 2x 100.0 1x 0x 0.0 2015 2016 2017 2018 2019 2020 2021 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, S&P LCD, Morgan Stanley Fixed Income Research, as of 12/26/2014 Note: Excludes Defaulted Facilities for observation period only Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 11 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Debt Is Rising But Remains Low Relative to Equity Top 500 Stocks (ex-Financials) Net Debt ($ Billions) Through 4Q 2014 2500 Top 1500 Net Debt-to-Equity Through Q4 2014 110% 2300 100% 2100 90% 1900 1700 80% 1500 70% 1300 60% 1100 50% 900 89 91 93 95 97 99 01 03 05 07 09 11 13 40% 89 91 93 95 97 99 01 03 05 07 09 11 13 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 12 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Is This Credit Cycle a Repeat of the 1990s? We Could See S&P Near 3000 by Cycle End (bp) 1800 Historical High Yield Spreads EPS vs SPX Level 2014 - 2020E 180 1600 1991-2002 2002-2008 2008-Current 1400 SPX Level: 3000 EPS 170 3000 SPX Level 1200 160 1000 150 800 140 600 130 400 120 3500 2500 2000 Repair 6% CAGR 200 Recovery 20 39 58 77 96 Months from Spread Peak 1000 500 110 Expansion Downturn 0 1 1500 115 134 100 0 2014 2015 2016 2017 2018 2019 2020 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 13 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Part II: The Multiple, Earnings, and Margins • S&P 500 Price Target • The Market Multiple • Earnings and Margins Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 14 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Our Year-End 2015 Price Target Is 2275; We Are Above Consensus on EPS Morgan Stanley 12-Month S&P 500 Price Target Methodology EPS Landscape Probability of Scenario Bull Case Growth Base Case Growth Bear Case Growth Expected Target 2015E 2016E Multiple Scenario Target 132.1 11% 124.0 4% 111.9 (6%) 146.6 11% 131.0 6% 111.9 0% 18.8x 2750 33.0% 17.4x 2275 10.1% 15.2x 1700 (17.7%) 20% 60% 20% Upside / (Downside) 2255 2067 Current S&P 500 Price Morgan Stanley and Consensus S&P 500 Earnings Estimates As of March 2015 Consensus MS Estimates $119 $124 $119 2014 $120 2015E Source: Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 15 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Multiples Are Above Average Levels – Multiple Expansion Occurs with Higher Real Rates Top 500: Price-to-Forward Earnings Through March 2015 P/E Ratio vs. Real Long-Term Treasury Yield Since 1930 20x 35x 18x 30 25 20 Median = 13.8x 15 P/E Ratio 16x 14x 12x 10x 8x 6x 10 4x < 0% 5 76 77 78 80 81 83 84 85 87 88 90 91 93 94 95 97 98 00 01 02 04 05 07 08 10 11 12 14 0-1% 1-2% 2-3% 3-4% 4-5% 5-6% > 6% Real Long-Term Treasury Yield Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 16 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy 2015 Estimates Have Fallen Much More Sharply Than Average Annual S&P500 Consensus EPS As of March 2015 Consensus EPS Growth Forecasts 1976 - 2014 $140 16% $135 14% $130 2016E 2015E $135.61 2014E $125 $119.72 2013 12% $120 2012 10% $115 8% $110 $119.31 $110.67 $105 6% $103.21 $100 Jan-11 Jun-11 Nov-11 Apr-12 Sep-12 Feb-13 Jul-13 Dec-13May-14 Oct-14 Mar-15 4% Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Source: Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 17 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy S&P 500 Growth Estimates S&P 500 ex-Fin S&P 500 ex-Fin & Energy S&P 500 ex-Energy Discretionary Materials Industrials Technology Tech ex-Apple Utilities Telecom Health Care Staples Energy EPS Growth 2014E 2015E 9.3% (1.8%) 10.6% 6.8% 8.6% 7.4% 9.6% 11.5% 8.2% (1.4%) 10.1% 11.6% 10.8% 5.6% 8.2% 2.1% 7.1% 2.1% 28.7% 5.9% 15.7% 8.9% 2.4% 0.2% 1.7% (57.6%) Revenue Growth 2014E 2015E 3.6% (1.1%) 4.8% 4.2% 4.4% 4.0% 7.0% 4.4% (1.0%) (5.2%) 4.2% 5.4% 3.0% 4.1% 0.4% 1.5% 5.3% (0.3%) (3.5%) 4.9% 11.2% 10.4% 2.5% 1.3% (2.2%) (29.3%) Source: Thomson Reuters, Morgan Stanley Research. Note: Bottom-up consensus estimates. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 18 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Companies Are Releasing Negative Guidance; We Expect Q1 EPS to Exceed Estimates S&P 500 Quarterly Earnings Surprise (%) Ratio of Negative-to-Positive At T=0 S&P 500 Guidance Relative to Consensus Expectations 20% 9 S&P 500 15% T=0 is end of Quarter S&P 500 Ex Fin 8.00 10% 8 5% 7 Average = 2.67 (Since 1Q05) 6 5.15 4.48 5 3.653.29 2.34 2.452.922.89 2.642.86 3 2.23 2.00 2 1.07 1.49 1.12 1.55 0.96 1 4 0% (5%) 2.912.893.13 (10%) (15%) 4Q14 2Q14 4Q13 2Q13 1Q15 4Q12 3Q14 2Q12 1Q14 4Q11 3Q13 2Q11 1Q13 4Q10 3Q12 2Q10 1Q12 4Q09 3Q11 2Q09 1Q11 4Q08 3Q10 2Q08 1Q10 4Q07 (20%) 0 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 19 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Margins Have Expanded, Driven Primarily by Mega Caps 40% Top 1500 Gross, EBIT, and Net Margin Through 2016E Gross Margin (LHS) 16% 35% EBIT Margin (RHS) 14% Net Margin (RHS) 30% 12% 25% 10% 20% 8% 15% 6% 10% E 5% 4% 15% 10% Top 1500: Net Margins by Market Capitalization, Through 2016E Large Mid Mega Small 5% 0% E (5%) 2% 0% 0% 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 16 (10%) 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 16 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 20 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Part III: Market Microstructure • Market Dynamics • Style: Growth vs. Value • Substance: Quality vs. Junk • Size: Large vs. Small • Capital Use and Its Consequences Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 21 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Hedge Funds in Aggregate Are Essentially Long the SPX; Alpha Generation Has Fallen Correlation of HFRI Equity Hedge Index with S&P 500 (Rolling 60 Months), Jan 1990 - Feb 2015 1.0 0.8 Alpha Correlation 0.9 0.7 0.6 0.5 0.4 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% (2%) (4%) Annualized Excess Return of HFRI Equity Hedge Index after Equity Market, Size, Quality, and Style Factors (Rolling 60 Mos.) Jan 1990 - Feb 2015 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 End of 60-Month Period End of 60-Month Period Source: Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 22 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Optimize Your Ability to Pick Stocks on a Bottom-Up Basis! Highly Idiosyncratic Industries Have Either Eclectic Stocks or Unique Common Risk Factors, 60-Month Regression Highest Industry Specific Risk Industry Wireless Telecommunication Services Multi-Utilities Electric Utilities Airlines Biotechnology Gas Utilities Real Estate Investment Trusts (REITs) Food Products Independent Power Producers & Energy Traders Pharmaceuticals Industries with Heavy Factor Exposure Tend to Come From Sectors with Low Sector-Specific Risk, 60-Month Regression Lowest Industry Specific Risk Risk Percentage Industry Specific 80.2% 72.3% 66.6% 64.8% 59.2% 53.3% 49.8% 49.7% 48.8% 48.6% Industry Machinery Capital Markets Chemicals Electronic Equipment, Instruments & Components Media Auto Components Insurance Household Durables IT Services Containers & Packaging Industry Specific Risk Percentage 12.8% 13.3% 14.7% 15.4% 16.7% 17.5% 19.1% 19.7% 19.8% 20.0% Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 23 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Stock-Specific Risk Is Near 5-Yr Highs; Alpha Generation in Tech, Retail Should Be High Top 500: Stock Specific Risk, Rolling 252-Day Through March 31, 2015 Best Factor Alpha & Performance Spread Annualized, Since Dec. 1984 25% 90% Alpha 80% 20% Performance Spread 70% 15% 60% 50% 10% 40% 30% 5% 20% 05 07 09 11 13 Banks/Div. Fin. 03 Insurance 01 Media 99 Industrials 97 Materials 95 Utilities 93 Staples 91 Autos/Dur. 89 Energy 87 Health Care 85 Retailing 83 Tech 0% 10% Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 24 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Equity Market and Hedge Fund Macro Variable Sensitivity Equity Market Sensitivity to Macro Variables April 1983 - August 2014 Macro Factor Yield Curve Slope Dollar Index Baa Spread Change in Factor +1% +6% +1% Exp. Market Return (4.3%) (1.1%) (4.0%) Hedge Fund Macro Variable Sensitivity Monthly Regression Coefficients: CS Indices Begin Jan. 1994; HFRI Indices Begin Jan. 1990 Through August 2014 1.5 1.0 0.5 Spreads 0.09 Dollar 0.07 Oil 0.04 0.02 0.0 (0.5) (0.01) (0.04) (0.06) (1.0) (1.5) (0.09) (0.11) Source: Haver, ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 25 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Energy Works Best in a Telegraphed Tightening Scenario Telegraphed Rate Hike Scenario: 5/31/04-11/30/04 Scenario Top 10 Bottom 10 Sectors/Cohorts Energy Information Technology High Beta Health Care Materials Junk Low Beta Value Cyclicals Small Neither Growth/Value Large Cap High Quality Utilities Mega Cap Neither Cyclicals/Defensives Industrials Mid Cap Financials Consumer Discretionary Exp. Return 10.45% 8.30% 7.49% 7.29% 7.07% 6.92% 6.81% 6.72% 6.66% 6.51% 5.91% 5.82% 5.55% 5.53% 5.52% 5.49% 5.45% 5.20% 4.02% 3.93% Industries Metals & Mining Energy Equipment & Services Oil, Gas & Consumable Fuels Personal Products Communications Equipment Internet Software & Services Biotechnology Chemicals Tobacco IT Services Household Durables Electronic Equipment, Instruments & Components Diversified Financial Services Specialty Retail Multiline Retail Construction & Engineering Air Freight & Logistics Banks Airlines Thrifts & Mortgage Finance Exp. Return 18.49% 13.69% 11.35% 10.10% 9.28% 8.72% 8.42% 8.32% 8.13% 8.11% 3.91% 3.76% 3.63% 2.97% 2.84% 2.34% 1.97% 0.38% 0.23% (2.84%) Ticker CSCO ORCL AAPL MA SLB UNH MON COP KO MO IBM GE C GILD INTC AMGN T UPS BRK.B VZ Company Cisco Systems Inc Oracle Corp Apple Inc Mastercard Inc Schlumberger Ltd Unitedhealth Group Inc Monsanto Co Conocophillips Coca-Cola Co Altria Group Inc Intl Business Machines Corp General Electric Co Citigroup Inc Gilead Sciences Inc Intel Corp Amgen Inc AT&T Inc United Parcel Service Inc Berkshire Hathaway Verizon Communications Inc Exp. Return 14.88% 14.05% 14.00% 13.07% 12.66% 12.31% 12.27% 10.67% 10.09% 9.48% 4.50% 4.50% 4.25% 4.13% 3.55% 3.46% 3.37% 3.30% 2.71% 2.67% Source: Haver, ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 26 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Growth Versus Value • Correlation Between Growth and Value Stocks Has Rolled Over From Prior Highs • Value Looks Expensive vs. History While Growth Is Less So • We Are Neutral on Style – A Barbell Strategy on Style • We Believe Investors Should Focus on Industries That are Cheaper Than the Market, But Which Are Likely to Grow Faster Than the Market Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 27 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Morgan Stanley Has Built a Proprietary Model for Identifying Growth and Value Factors Considered for Growth Model Variable IBES Long-Term Growth Rate EPS Growth Rate EPS Growth Rel. to Estimate Dispersion Breadth of EPS Revisions Indicated Dividend Yield Trailing Dividend Yield Percent Change in Headcount Return on Equity % Change in Shares Outstanding Sales Growth R&D-to-Sales Capital Spending-to-Depreciation Price-to-Book Tangible Price-to-Book Cash Yield Total Debt-to-Market Capitalization Implication for Growth Status Positive Positive Positive Positive Negative Negative Positive Positive Negative Positive Positive Positive Negative Negative Negative Negative Factors Chosen for Growth Stock Model IBES Long-Term Growth Rate Indicated Dividend Yield Price-to-Book Total Debt-to-Market Capitalization Source: Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 28 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Growth and Value Betas Are Similar, While Correlations Have Rolled Over Growth vs. Value: 36-Month Rolling Correlation of Returns Through March 2015 Beta of Growth/Value Relative to the Market Through March 2015 1.0 Growth 1.5 0.9 Value 0.8 36-Month Correlation 1.3 1.1 0.9 0.7 0.5 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0.3 76 79 82 85 88 91 94 97 00 03 06 09 12 72 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 29 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Growth Outperformed Value for Most of 2014 and Revisions Have Turned Up Recently Growth vs. Value: Relative Trailing 12-Month Performance: Through March 2015 0.04 80% 0.03 0.02 Value Outperforms 20% 0% (20%) (40%) (60%) Growth Outperforms Earnings Revisions 12-Month Relative Return 60% 40% Growth and Value Revisions Trends 3-Month Moving Average Through March 2015 0.01 0.00 (0.01) (0.02) (0.03) (0.04) (0.05) (80%) Growth - Market Value - Market (0.06) 70 72 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 30 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy We Have Built a Proprietary Model for Identifying High / Low Quality U.S. Stocks Measures of Intrinsic Stock Quality Used in the MS Quality Model Included In Final Model Equity Market beta Negative - Quality Stocks Have Lower betas Market Cap (logarithm) Positive - Quality Stocks Are larger T Statistic of EPS Positive - Quality Stocks Have More Stable EPS T-statistic of Dividends/Share Positive - Quality Stocks Have Stable Dividends T-stat of { Dividends/Share Growth Rate } Positive - Quality Stocks Grow Their Divs/Share "Ever Paid a Dividend" Flag Positive - Paying a Dividend Associated with Quality T-statistic of ROE Positive - Quality Stocks Have More Stable ROE Daily Share-Base Turnover Negative - Quality Stocks Have Stable Investor bases Volatility of ROE T-statistic of ROE Growth Rate Sales Growth (1 yr) (%) IBES Long-Term Growth Rate Net Margin Net Cash Ratio Volatility ROE Total Debt / Market Cap Indicated Dividend Yield Trailing Dividend Yield T-statistic of EPS Growth Rate Other Factors Tested Negative - Quality Stocks Have Less Volatile ROE Negative - Quality Stocks Already Have High ROE Positive - Quality Stocks Have Grown sales Negative - Quality Stocks Have Less Growth potential Positive - Quality Stocks Have Higher Net Margins Negative - Stable Net Cash Ratios Associated with Quality Positive - High ROE Associated with Quality Negative - High Debt Loads Not Associated with Quality Positive - Higher Dividend Yield Associated with Quality Positive - Higher Dividend Yield Associated with Quality Positive - Quality Stocks Have Growing EPS Source: Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 31 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy “Moderate” Quality Has Been the Long-Term Winner Cumulative Performance of Beta-Hedged Quality Quartiles Through Mar 2015 Residuals of the Junk-Quality Spread Mar 2014 - Mar 2015 300% Cumulative Return of Monthly Returns 3.0% Junk Stocks Outperform 2.0% 1.0% 0.0% (1.0%) (2.0%) (3.0%) (4.0%) (5.0%) Mar-14 May-14 Jul-14 Sep-14 Nov-14 Jan-15 Mar-15 250% 200% Q1 Q2 Q3 150% Q4 100% 50% 0% (50%) (100%) 81 83 85 87 89 91 93 95 97 99 01 03 05 07 09 11 13 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 32 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Large vs. Small • Mega-Caps Have Record Margins While Small-Cap Profitability Is Modestly Below its Long-term Average • Despite Small-Caps Being Somewhat Expensive vs. Mega-Caps, the Group Has Similar Dividend Yields • Small-Caps Offer Higher Sales Growth versus Mega-Caps • Recent Deal Activity Is also Near All-time Lows, Providing Upside Should Management Confidence Grow • There Are High Quality Small Cap Companies Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 33 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Small-Cap Stocks Outperformed in March Return Residuals by Market Cap Through March 2015 6.0% 4.0% 2.0% Mega Large Mid Small 0.0% (2.0%) (4.0%) (6.0%) Last Month Last 3 Months Last 6 Months Last 12 Months Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 34 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Magnitude of Future Small-Cap Margin Expansion and Faster Growth Are Positives 15% 10% Top 1500 Sales Growth: Mega vs. Small Caps 1974 Through Q4 2014 Top 1500: Net Margins by Market Capitalization, Through 2016E 35% Large Mega 30% Mid Small 25% Mega Small 20% 15% 5% 10% 5% 0% E (5%) 0% (5%) (10%) (15%) (10%) 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 16 (20%) 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 35 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Reward for Buybacks Varies By Size of Company; An Improving Small-Cap M&A Cycle Would Be Beneficial Efficacy of Buybacks by Market Cap Last 12 Months Small Cap Offer Intensity Q4 1983 - Q4 2014 5% 2% Small, Mid, & Large (1%) Share Issuance Rewarded Mega 1% # offers/# stocks Share Buybacks Rewarded 4% 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 36 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Historically, Generating Alpha among Mega-Caps Was Feasible; Blended $100 Billion Stock Ranking Likes BAC the Most, XOM the Least Spread in Annual Returns 14% Mega-Caps: 75%-ile to 25%-ile Return Spread for Simulated Portfolios with a Basic Weighting Scheme 1964 to 2014 12% 10% 8% 6% 4% 2% 0% 64 67 70 73 76 79 82 85 88 91 94 97 00 03 06 09 12 Weight BAC GILD IBM JPM CVX BMY DIS XOM MS Analyst View less WITP Value Rank 15% 3 8% 8% 2 8% 1 8% 3 (5%) 41 (3%) 36 (3%) 35 (2%) 34 MS vs Cons. 3-Year EPS CAGR Rank Value 20% 3% 4 8 1% (1%) 25 0% 17 6% 2 2% 7 35 (3%) (8%) 41 Forecasted Total Return Value Rank 20% 29% 2 14% 10 11 14% 10% 21 2% 39 7% 35 9% 27 2% 38 Quant Model Rank Value 25% 9.6% 7 2 25.7% 27.2% 1 15.0% 6 (17.4%) 37 38 (17.6%) (13.7%) 36 34 (12.8%) "Quantamental" Approach Value Rank 20% 8.3 2 6.5 1 17.0 12 9.5 3 26.0 29 29.5 38 28.0 37 33.0 41 Blended Rank 3.8 4.6 10.0 10.2 29.4 30.9 34.1 37.6 Source: ClariFi, Thomson Reuters, Morgan Stanley Research. For important disclosures regarding companies that are the subject of this screen, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 37 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Capital Use and Its Consequences • Enormous Cash Balances Exist • ALERT: The Acquisition Likelihood Estimate Ranking Tool Conclusion: We See M&A and Dividend Growth as Likely Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 38 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy US Corporate Balance Sheets Hold $1.7 Trillion in Cash Share of Cash Balances by Sector (Ex-Financials) As of Q4 2014 40% 30% $1.2 25% $1.0 20% $0.8 15% 18% 17% 13% 10% $0.6 7% 6% 6% Energy $1.4 34% Other 35% Staples $1.6 5% $0.4 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99 01 03 05 07 09 11 13 Discretionary $0.0 Industrials 0% $0.2 Health Care $1.8 Cash Balances Top 1500 Stocks (Ex-Financials, $T) Through Q4 2014 Technology $2.0 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 39 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Investors Rewarded Dividends Last Year Efficacy of Capital Uses by Time Period: One-Year Return Top vs. Bottom Tertile (T1-T3), 1969 - February 2015 Capital Spending 19691976 0.3% 19771994 (3.4%) 19952001 (6.4%) 20022008 1.1% 20112014 (7.2%) R&D Expenditures 9.4% 1.2% 7.1% (2.6%) 3.1% (7.9%) (5.8%) (13.8%) (9.0%) 2.3% 2.8% (1.6%) 1.4% (2.5%) (3.0%) (9.5%) (1.6%) Internal Growth External Growth Reduce Leverage Return to Shareholders M&A Cash Only Stock Only Blend Change in Debt-toAssets 2.1% (0.1%) (1.1%) 2.3% (0.2%) Total Yield Dividend Yield Share Buybacks (3.1%) (3.1%) (0.2%) 1.3% 0.6% 2.9% 2.4% 0.1% 10.2% (1.0%) 0.6% (1.7%) 5.5% 2.0% 5.8% Source: ClariFi, Thomson Reuters, Morgan Stanley Research Note: T1 defined as high capital spenders, high R&D spenders, high shareholder yield, low change in total debt. For M&A the figures represent median performance of acquirers vs the market. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 40 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Dividend Yield Is Rewarded Episodically; Buybacks Have Been Effective Long Term Dividend Yield 12-Month Long/Short (Q1-Q5) Return Spread Through March 2015 100% 60% 40% Dividend Yield Rewarded 20% 0% (20%) (40%) (60%) (80%) Dividend Yield Punished 12-Month return spread (Q1-Q5) 12-Month return spread (Q1-Q5) 80% Reduction in Shares Outstanding 12-Month Long/Short (Q1-Q5) Return Spread, Through March 2015 80% 60% Buybacks Rewarded 40% 20% 0% (20%) Buybacks Punished (40%) (60%) (100%) 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Note: T1 defined as high capital spenders, high R&D spenders, high shareholder yield, low change in total debt. For M&A the figures represent median performance of acquirers vs the market. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 41 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy US Companies Switched More to Buybacks from Dividends Relative to Long-Term History; But C-Level Execs Are Paid More in Restricted Stock Top 500: Total Yield, Dividend Yield, and Buyback Yield Through March 2015 7% 9% Dividend Yield (LHA) 6% 5% Buyback Yield (LHA) Total Yield (RHA) 100% 8% 90% 7% 80% 6% 70% 4% 5% 3% 4% Percentage of CEOs from S&P 500 Companies Receiving Equity-Based Compensation 1992 Through 2011 60% 50% 2% 1% 40% 3% 30% 2% 20% CEOs with Option Grants 10% CEOs with Restricted Stock Grants 1% 0% 0% 0% 64 67 70 73 76 79 82 85 88 91 94 97 00 03 06 09 12 15 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 Source: Morgan Stanley Research, Murphy, Kevin J., “Executive Compensation: Where We Are, and How We Got There,” Handbook of the Economics of Finance, December 19, 2012. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 42 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Our Acquisition Likelihood Estimate Ranking Tool, ALERT, Contains 10 Factors ALERT Factor Size Deal Intensity (Annual) Quality Deal Intensity (Annual) Sector Deal Intensity (Annual) Health Care Indicator Sector Relative Price-to-Book Dividend Yield Debt-to-Assets Market Cap Rank Mega-Cap Cohort Indicator Industrials Indicator Interpretation Higher Means More Likely Offer Higher Means More Likely Offer Higher Means More Likely Offer If Health Care Means More Likely Offer Cheaper Means More Likely Offer Lower Means More Likely Offer Higher Means More Likely Offer Smaller Cap Means More Likely Offer If Mega-Cap Means Less Likely Offer If Industrial Means Less Likely Offer Parameter Sign + + + + + + - Source: Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 43 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Large Stocks with the Highest Likelihoods of Receiving Offers according to ALERT Liquid Stocks from Each Sector that Are in the Top Quintile of ALERT as of January 2015 Ticker RDC DNR PTEN RKT MLM RGLD GPK LMCA CVC LAMR NVR BC DNKN AMCX SBH GNC CAB RAD INGR WWAV HAIN SFM AVP HLF NUS Company Name Rowan Companies Plc Denbury Resources Inc Patterson-Uti Energy Inc Rock-Tenn Co Martin Marietta Materials Royal Gold Inc Graphic Packaging Holding Co Liberty Media Corp Cablevision Sys Corp -Cl A Lamar Advertising Co -Cl A Nvr Inc Brunswick Corp Dunkin' Brands Group Inc Amc Networks Inc Sally Beauty Holdings Inc Gnc Holdings Inc Cabelas Inc Rite Aid Corp Ingredion Inc Whitewave Foods Co Hain Celestial Group Inc Sprouts Farmers Market Avon Products Herbalife Ltd Nu Skin Enterprises -Cl A Mkt. Cap ($B) Price ($) 2.8 18.07 2.4 7.84 19.37 2.3 63.08 8.9 7.4 137.36 64.69 4.9 14.55 4.7 11.9 39.48 5.4 18.16 5.3 59.58 5.3 1,353.13 51.34 4.8 4.7 47.32 4.6 75.33 34.40 4.6 4.1 48.01 4.0 57.12 8.79 7.2 6.2 78.65 5.8 44.65 5.4 63.86 5.3 35.80 7.97 3.3 2.8 42.91 2.6 61.12 Sector Energy Energy Energy Materials Materials Materials Materials Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Discretionary Consumer Staples Consumer Staples Consumer Staples Consumer Staples Consumer Staples Consumer Staples Consumer Staples Consumer Staples Combined Rank Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Ticker DVA EW BCR INCY MNK HSP JAZZ DGX ALKS AHL DST FEIC JDSU LXK ZNGA LVLT FTR WIN TE GXP STR Company Name Davita Healthcare Partners Edwards Lifesciences Corp Bard (C.R.) Inc Incyte Corp Mallinckrodt Plc Hospira Inc Jazz Pharmaceuticals Plc Quest Diagnostics Inc Alkermes Plc Aspen Insurance Holdings Ltd Dst Systems Inc Fei Co Jds Uniphase Corp Lexmark Intl Inc -Cl A Zynga Inc Level 3 Communications Inc Frontier Communications Corp Windstream Holdings Inc Teco Energy Inc Great Plains Energy Inc Questar Corp Mkt. Cap ($B) Price ($) 16.3 80.59 13.8 140.61 13.2 167.93 13.1 88.79 12.2 124.76 10.8 87.82 10.6 168.86 75.80 10.1 10.0 60.10 2.7 47.57 3.7 111.57 3.3 78.26 3.1 12.98 2.4 42.92 2.3 2.78 11.8 54.23 6.8 7.32 5.0 7.92 5.0 19.64 4.6 26.95 4.6 24.00 Sector Health Care Health Care Health Care Health Care Health Care Health Care Health Care Health Care Health Care Financials Information Technology Information Technology Information Technology Information Technology Information Technology Telecommunication Services Telecommunication Services Telecommunication Services Utilities Utilities Utilities Combined Rank Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Note: ALERT rankings are based on a weighted combination of 10 factors. MOST, BEST, and analyst ratings are not included in these factors. Model rankings are updated based on current valuations. Note that this is a purely quantitative model and it makes no adjustment for other qualitative factors that will often be key considerations for any acquisition. While stocks that are ranked highly according to this model have historically had elevated probabilities of receiving offers, it is still unlikely that any individual name from this rankings list will receive an offer over the next 12 months. For important disclosures regarding the companies that are the subject of this screen, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures. Prices updated as of 04/02/2015. Source: ClariFi, Thomson Reuters, Morgan Stanley Research. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 44 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Part IV: Sector Bets • Sector Recommendations – Overweights: Discretionary, Energy – Market-Weights: Materials, Health Care, Financials, Telecoms, Technology – Underweights: Utilities, Industrials, Staples • Industry Selection Model: PRISM Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 45 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy We Are OW Discretionary and Energy, UW Utilities, Industrials, and Staples 2.3% Energy Staples Industrials Discretionary Health Care Financials Technology 0% Overweights - Discretionary, Energy Market-Weights - Materials, Health Care, Financials, Telecoms, Technology Underweights - Utilities, Industrials, Staples Staples 3.1% Industrials 3.2% Utilities 5% Technology 8.1% Telecom 9.8% Utilities 10.3% 10% Telecoms 12.6% Health Care 14.7% Materials 16.2% 15% Financials 19.7% Materials 20% Morgan Stanley Sector Recommendations As of April 2015 Discretionary 25% 5% 4% 3% 2% 1% 0% (1%) (2%) (3%) (4%) (5%) (6%) Energy S&P 500 Sector Weights As of April 2015 Source: Capital IQ, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 46 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Overweight Rated Sectors • Energy: – – – • We Are Retaining Our Energy Position of 12% vs the Benchmark Weight of 8.1% Energy Earnings Revisions Will Assuredly Be the Most Negative of Any Sector in the Market, But This Doesn’t Always Mean the Sector Underperforms-- There’s Ample Precedent For Energy Stocks to Work With Negative Earnings Revisions But We Do Worry Our Upgrade Could Be Premature if Oil Falls to Cash Cost Consumer Discretionary: – – We Retain Our 16% Large Overweight Position vs. the Benchmark Weight of 12.7% We Like the Fact that the Low End Consumer Benefits From Lower Fuel at the Pump, But Many Low End Consumer Stocks Have Been Quickly Re-Rated Higher, So Our Bets Now Are More On Brands Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 47 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Market-Weight Rated Sectors • Financials: – – – • Materials: – – • – – After Recommending Health Care for the Last Four Years, We Reduced Our 2015 Outlook Based on a More Balanced Risk-Reward We Still Prefer Health Care to Staples, But Health Care Price-to-Forward Earnings Has Expanded to Ten Year Highs and We Are Concerned About Drug Price Inflation and its Impact on the Distribution Industry We Hold 15% of Our Portfolio in Healthcare vs. the S&P 500 Benchmark Weight of 14.8% Telecommunications: – • Sector Is Only 3.2% of the S&P 500 and Is Weighted About 2/3rd Toward Chemicals We Have 4% Exposure in Our Portfolio. The Majority of Our Picks Are in Chemicals Health Care: – • We Hold 18% vs. the Benchmark Weight of 16.3% During Our Mid-Year Outlook We Were Cautious on Financials as We Were Worried about Fundamental Trends, But the Sector Has Modestly Outperformed the S&P 500 Since Then, Despite the Less Favorable Rate Environment We Are Constructive On the Duration of the Cycle but Continue to Prefer Retailers to Banks Our Only Telecom Holding is a 2% Position in VZ vs the 2.3% Benchmark Weight Technology: – – – – We Hold a 19% Weight in Technology vs the Sector Benchmark of 19.6% It Has Been Difficult to Implement a Quantamental Investment Discipline and We Have Moved Outside the Discipline to Find Ideas Sector Looks Attractive in Aggregate on Valuation, Cash Flows, and Cash Balances, But Few Individual Securities Embody the Attributes of the Whole Select Industries Are Among the Fastest Growing in the Market, and Fast Growing Stocks that are Cheap Typically Underperform Fast Growing Stocks that Are Expensive Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 48 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Underweight Rated Sectors • Utilities: – – • Industrials: – – – • We Hold 1% of the Portfolio in Utilities vs the Benchmark Weight of 3.1% We Remain Underweight the Sector Even As Utilities Have Underperformed the Market Recently We Haven’t Been Recommending Industrials For a Year and hold 8% vs the Benchmark Weight of 10.3% We Have Negative Bias toward the Sector Given our View that Capital Spending Will Disappoint However, Industrials Generally Screen Well on at Least One of Our Models (MOST and BEST, but Not Both) and We Want to Retain Some Exposure to China Consumer Staples: – – – We Remain Underweight Staples: The Sector Is 5% of the Portfolio vs. the Benchmark Weight of 9.8% We Remain Broadly Concerned about Valuation and Estimate Achievability for this Group Our Biggest Positions in Staples Are WWAV and SFM Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 49 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Margins Matter For Tech While Forecasted Revenue Growth Does Not Appear Correlated to EV-to-EBITDA Multiples; Tech Returns More Cash to Shareholders Tech Stock Performance: Improving Margins vs Sales Growth Through Q4 2014 Top 50 Tech: NTM Forecast Revenue Growth Vs Multiple 200 20% 150 15% 100 EV-to-EBITDA Cumulative 1-Month Relative Return 25% 10% 5% 50 - (50) 0% (100) (5%) 12/09 12/10 12/11 12/12 12/13 12/14 (150) (10%) 0% 10% 20% Forecast Revenue Growth 30% 40% Top 500 Technology: Relative Total Yield Through January 31, 2015 3% 2% 1% 0% (1%) (2%) (3%) (4%) 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 Source: ClariFi, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 50 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy PRISM Balances Weights Among Several Categories of Factors to Estimate Alpha PRISM Models: Factor Weights Model Valuation Category Factor Cyclicals 9.5% Yields in excess of the market yield are positive Free Cash Flow-to-Enterprise Value 5.2% High free cash flow to enterprise value is positive Price-to-Trailing Earnings (Sector Relative) Price-to-Forward Earnings (Market Relative) 17.7% 10.6% Growth / Sentiment Profitability Total Yield IntraIndustry Notes ("Positive" = increases expected alpha) Dividend Yield (Market Relative) Price-to-Forward Earnings High trailing P/E relative to its sector is negative High forward P/E relative to the market is negative 8.5% High forward P/E is negative 8.0% High total yields (dividends and net buybacks) are positive Valuation Total 25.4% ROE Variability 13.9% Profitability Total 13.9% 6-Month Price Momentum 14.2% 12-Month Price Momentum (Market Relative) 18.3% 16.5% Growth / Sentiment Total 32.5% 16.5% 34.3% Volatile ROE is negative (i.e., more-cyclical cyclicals underperform) 0.0% Strong 6-month price momentum is negative Strong 12-month price momentum relative to the market is positive Industry Earnings-Revision Dispersion 7.4% Dispersion of earnings revisions among companies is negative Forward Price-to-Earnings Disp. (Market Rel.) 14.7% Dispersion in forward P/E among constituent stocks is negative 11.9% Dispersion of trailing 3-month constituent stock returns is negative 3-Month Return Dispersion Balance Sheet and Capital Use Defensive / Neither Intra-Industry Total 0.0% Accruals 3.5% Accruals (differences between cash flow and earnings) are negative Change in Shares Outstanding (Sector Rel.) 5.8% Adding shares faster than sector is negative Price-to-Cash (Z-Score) 8.1% Debt-to-Equity 34.1% High cash balances (vs own history) are positive 15.2% Inventory-to-Sales 10.8% Balance Sheet and Capital Use Total 28.2% 15.2% Overall Total 100.0% 100.0% Adam S. Parker, Ph.D, (212) 761-1755, [email protected] High leverage is negative High inventories relative to sales are negative Source: Morgan Stanley Research 51 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Favored and Disfavored Industries in PRISM PRISM Cyclical and Defensive/Neither Models Industries Ranked in Q1 and Q5 Industry Air Freight & Logistics Capital Markets Commercial Services & Supplies Communications Equipment Computers & Peripherals Gas Utilities Health Care Providers & Services Insurance Road & Rail Semiconductors & Semiconductor Equipment Tobacco Water Utilities Automobiles Biotechnology Building Products Construction Materials Diversified Consumer Services Electrical Equipment Health Care Technology Household Durables Internet & Catalog Retail Internet Software & Services Personal Products Real Estate Management & Development Thrifts & Mortgage Finance Adam S. Parker, Ph.D, (212) 761-1755, [email protected] Current Quintile Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q1 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Q5 Source: ClariFi, Thomson Reuters, Morgan Stanley Research 52 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Part V: Arrows in the Quiver and the MOST Strategic Portfolio • MOST: 3-Month Alpha Model • BEST: 24-Month Alpha Model • Alpha Screener Website • MOST Strategic Portfolio Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 53 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Stock Selection: There Are Important Synergies Between Fundamentals and Quant 8% 13% 52% 12% 10% Annualized Average 1-Month Q1 - Q5 Return Spreads for BEST, MOST and Combined, 1979-2011 Combined Spread Obtained from Quintiles Q1/Q2 - Q4/Q5 57% Hit rate: 44% 6% 6% 4% 2% 0% Fundamental "MOST" 14% 14% 9% Synergy Note: Fundamental is the MS analysts Overweight vs. Equal / Underweights from 2003 to 2010; "MOST" is the Q1Q5 spread from our alpha model; Synergy is Overweight rated stocks in Q1 of MOST less Equal / Underweight in Q5. Performance is annualized for MOST, "realized" during the recommendation period of the synergy. Annualized Q1-Q5 Spread 14% Performance of Various Approaches to Investing 2003 to 2010 13% 11% 12% 11% 10% 10% 9% 8% 7% 6% Q1-Q5 BEST Q1-Q5 MOST Q1/Q2 -Q4/Q5 Synergy Source: Morgan Stanley Research Note: Past performance is no guarantee of future results. Data as of October 31, 2010. Results shown represent total absolute return (including dividends) and exclude brokerage commissions. These figures are not audited. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 54 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Our Alpha Models Produced Positive Alpha Over the Last Year Alpha Models Return Residuals, Through March 2015 12% 10% 8% MOST BEST Synergy 6% 4% 2% 0% (2%) Last Month Last 3 Months Last 6 Months Last 12 Months Source: ClariFi, Thomson Reuters, Morgan Stanley Research. Past performance is no guarantee of future results. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 55 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Stock Selection: 2-Year (BEST) and 3-Month (MOST) Alpha Models for all U.S. Stocks MOST vs. BEST Factor Weights: 1972-2009 (BEST) and 1979-2010 (MOST) Macro-cyclicals MOST Balance Sheet and Capital Use Technicals Growth & Sentiment Profitability Valuation Category Factor 36-Month Forward Earnings-to-Price Z-score Cash-to-Price Dividend Yield Earnings-to-Price Free Cash Flow-to-Enterprise Value Operating Cash Flow-to-Price Price-to-Book Value Price-to-EBIT Price-to-EBITDA Price-to-Forward Earnings Price-to-Sales Total Yield Valuation Total Defensives BEST MOST Consumer Cyclicals BEST 20% MOST BEST 10% 5% 18% 4% 13% 11% 8% 27% 15% 5% 7% 4% 30% 32% Gross Margin 3% 7% 5% 15% 6% 24% 38% 20% 57% 6% Incremental Margin 3% ROE Variability 5% Return on Invested Capital Profitability Total 24-Month Price Momentum 6-Month Price Momentum Estimate Dispersion Long Term Growth Forecast Sales Stability Sales Variability Up-to-Down Revisions Growth & Sentiment Total Bollinger Bands (10d, 21d, 63d) Breakout Signals (168d, 336d, 672d) Residual (21d) Technicals Total 36-Month CapEx-to-Sales Z-score Accruals Asset Turnover Assets - Debt Instantaneous Slope CapEx-to-Assets CapEx-to-Depreciation CapEx-to-Sales Cash-to-Assets Change in Shares Outstanding Debt-to-Assets Dividend Payout Ratio Inventory-to-Sales Net Cash Ratio Net Cash Variability Net Debt-to-Market Cap Y-o-Y Change in Debt-to-Capital Balance Sheet and Capital Use Total 3% 3% 22% 45% 28% 8% 44% 29% 36% Total 100% 100% 100% 100% 100% 100% 1% 1% 3% 5% 10% 10% 1% 24% 34% 4% 14% 9% 11% 7% 6% 9% 7% 7% 0% 6% 30% 23% 6% 5% 10% 23% 18% 5% 10% 17% 23% - 30% 12% 7% 12% - 4% 11% 5% 10% 8% 3% 10% 3% 7% 5% 1% 3% 8% 19% 10% 1% 14% 18% 18% 17% 6% Factors unique to BEST are highlighted in the table above Adam S. Parker, Ph.D, (212) 761-1755, [email protected] Source: Morgan Stanley Research 56 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Morgan Stanley Alpha Screener (www.morganstanley.com/equitystrategy) Data shown above are for illustrative purposes only. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 57 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy MOST Strategic Portfolio Relative Performance MOST Strategic Portfolio Performance December 31, 2014 to April 06, 2015 MOST Strategic Portfolio Performance December 31, 2010 to April 06, 2015 4.00% 100.0% 92.9% 80.0% 3.4% 3.50% 90.0% 78.3% 3.00% 2.5% 70.0% 2.50% 60.0% 50.0% 2.00% 40.0% 1.50% 30.0% 14.7% 20.0% 10.0% 1.00% 0.8% 0.50% 0.0% S&P Portfolio Relative Performance 0.00% S&P Portfolio Relative Performance Source: Capital IQ, Thomson Reuters, Morgan Stanley Research. Past performance is no guarantee of future results. Results shown represent total absolute return (including dividends) and exclude brokerage commissions. These figures are not audited Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 58 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy MOST Portfolio Performance Attribution MOST Strategic Portfolio Performance Attribution December 31, 2010 to April 06, 2015 Sector Overweight Consumer Discretionary Energy Relative Weight 7.3% 3.4% 3.9% Portfolio Sector Sector Weight Return 28.0% 91.7% 16.0% 144.0% 12.0% 22.0% Relative Return 10.9% 26.9% (2.3%) Sector Weight 20.7% 12.6% 8.1% S&P 500 Sector Relative Return Return 80.8% 2.5% 117.1% 38.8% 24.3% (53.9%) Sector Allocation 0.2% (0.2%) 0.4% Stock Selection 2.0% 1.6% 0.3% Total 2.2% 1.4% 0.8% Market-Weights Materials Health Care Financials Telecommunication Services Information Technology 1.8% 0.8% 0.2% 1.8% (0.3%) (0.7%) 58.0% 4.0% 15.0% 18.0% 2.0% 19.0% 94.4% 156.1% 201.3% 47.8% 13.0% 49.9% 6.4% 115.5% 59.6% (16.7%) (27.8%) (30.6%) 56.2% 3.2% 14.8% 16.2% 2.3% 19.7% 88.1% 40.6% 141.7% 64.5% 40.8% 80.4% 9.8% (37.6%) 63.5% (13.8%) (37.4%) 2.2% 2.4% 0.3% 2.3% (0.4%) (0.2%) 0.3% (0.3%) 3.7% 6.3% (2.8%) (0.2%) (7.3%) 2.2% 4.0% 8.6% (3.2%) (0.3%) (6.9%) Underweights Utilities Industrials Consumer Staples (9.1%) (2.1%) (2.3%) (4.7%) 14.0% 1.0% 8.0% 5.0% 115.3% 120.6% 72.1% 183.3% 38.7% 55.7% (3.1%) 101.7% 23.1% 3.1% 10.3% 9.7% 76.5% 64.9% 75.1% 81.6% (1.7%) (13.4%) (3.1%) 3.4% 2.2% 1.0% 0.8% 0.4% 8.1% 2.3% 0.3% 5.6% 10.3% 3.2% 1.1% 6.0% 0.0% 100.0% 92.9% 100.0% 78.3% 4.8% 9.8% 14.6% Total Source: Capital IQ, Thomson Reuters, Morgan Stanley Research Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 59 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy The MOST Strategic Portfolio Weight Ticker Company Price S&P 500 Portfolio 12.7% 16.0% Consumer Discretionary Latest Inclusion Inclusion MOST MS Analyst Date Quintile Rating Auto Components DAN Dana Holding Corporation 1.0% 21.69 20.37 1/20/2015 Q1 Overweight Media CBS CBS Corporation 1.0% 60.89 19.05 12/31/2010 Q1 Overweight Auto Components DLPH Delphi Automotive PLC 2.0% 83.81 69.06 5/30/2014 Q1 Overweight Hotels, Restaurants and Leisure HOT Starwood Hotels & Resorts Worldwide Inc. 1.0% 84.94 79.00 11/28/2014 Q2 Overweight Hotels, Restaurants and Leisure LVS Las Vegas Sands Corp. 1.0% 56.85 68.13 8/8/2014 Q5 Equal-Weight Textiles, Apparel and Luxury Goods NKE Nike, Inc. 2.0% 99.81 77.06 8/8/2014 Q2 Overweight Multiline Retail M Macy's, Inc. 1.0% 68.02 59.60 10/3/2014 Q5 Equal-Weight Automobiles HOG Harley-Davidson, Inc. 2.0% 61.64 56.49 10/13/2014 Q3 Overweight Media FOXA Twenty-First Century Fox, Inc. 3.0% 34.43 30.36 3/15/2013 Q1 Overweight Specialty Retail LB L Brands, Inc. 2.0% 94.86 50.49 4/26/2013 Q2 Overweight Food Products WWAV The WhiteWave Foods Company 2.0% 45.69 21.27 11/29/2013 Q4 Overweight Food and Staples Retailing WMT Wal-Mart Stores Inc. 1.0% 81.10 75.75 7/3/2014 Q1 Equal-Weight Food and Staples Retailing SFM Sprouts Farmers Market, Inc. 2.0% 35.77 31.79 11/28/2014 Q1 Overweight Oil, Gas and Consumable Fuels APC Anadarko Petroleum Corporation 1.0% 85.91 96.48 4/11/2014 Q5 Overweight Energy Equipment and Services SLB Schlumberger Limited 3.0% 86.11 108.38 8/8/2014 Q5 Overweight Oil, Gas and Consumable Fuels PSX Phillips 66 2.0% 78.64 63.62 1/20/2015 Q2 Overweight Oil, Gas and Consumable Fuels ETE Energy Transfer Equity, L.P. 2.0% 63.93 58.26 7/3/2014 NA Overweight Oil, Gas and Consumable Fuels OXY Occidental Petroleum Corporation 1.0% 76.58 79.77 11/28/2014 Q2 Overweight Oil, Gas and Consumable Fuels VLO Valero Energy Corporation 3.0% 59.74 55.93 5/9/2014 Q1 Overweight Overweight Consumer Staples 9.8% Energy 8.1% Financials 16.3% 5.0% 12.0% 18.0% Capital Markets KKR KKR & Co. L.P. 2.0% 22.84 23.98 2/21/2014 NA Banks FITB Fifth Third Bancorp 1.0% 18.98 21.63 7/3/2014 Q2 Overweight Insurance MMC Marsh & McLennan Companies, Inc. 2.0% 57.01 47.96 2/21/2014 Q2 Equal-Weight Banks BAC Bank of America Corporation 3.0% 15.56 15.82 11/29/2013 Q3 Overweight Real Estate Investment Trusts (REITs) CCI Crown Castle International Corp. 3.0% 84.95 67.55 11/23/2012 Q5 Overweight Consumer Finance AXP American Express Company 2.0% 79.78 92.42 11/28/2014 Q1 Overweight Banks HBAN Huntington Bancshares Incorporated 2.0% 11.07 10.70 2/17/2015 Q4 Overweight Banks JPM JPMorgan Chase & Co. 3.0% 60.56 42.42 12/31/2010 Q1 Overweight Healthcare Providers and Services MCK McKesson Corporation 4.0% 224.56 77.74 2/4/2011 Q1 Overweight Healthcare Providers and Services CAH Cardinal Health, Inc. 2.0% 90.03 38.31 12/31/2010 Q3 Equal-Weight Biotechnology BIIB Biogen Inc. 4.0% 413.01 330.48 9/5/2014 Q2 Overweight Healthcare Providers and Services AET Aetna Inc. 3.0% 107.93 91.98 1/20/2015 Q2 Overweight Pharmaceuticals PFE Pfizer Inc. 2.0% 34.51 18.15 9/16/2011 Q1 Equal-Weight Health Care 14.8% Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 15.0% Source: Capital IQ, Thomson Reuters, Morgan Stanley Research 60 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy The MOST Strategic Portfolio (cont’d) Weight Inclusion MOST MS Analyst Latest Inclusion Date Quintile Rating 2.0% 104.46 61.72 9/17/2012 Q3 Overweight Union Pacific Corporation 1.0% 106.48 65.45 1/4/2013 Q5 Overweight BA The Boeing Company 1.0% 151.16 128.51 7/3/2014 Q2 NA Airlines DAL Delta Air Lines, Inc. 1.0% 41.78 31.76 2/21/2014 Q1 Overweight Machinery SPW SPX Corporation 1.0% 86.39 101.85 9/12/2014 Q2 Overweight Aerospace and Defense UTX United Technologies Corporation 2.0% 117.97 78.85 12/30/2010 Q3 Overweight Equal-Weight Ticker Company Aerospace and Defense HON Honeywell International Inc. Road and Rail UNP Aerospace and Defense Industrials S&P 500 10.3% Information Technology 19.6% Price Portfolio 8.0% 19.0% Internet Software and Services GOOGL Google Inc. 3.0% 544.91 529.80 11/29/2013 Q2 Communications Equipment CSCO Cisco Systems, Inc. 2.0% 27.26 28.07 1/20/2015 Q2 Overweight Apple Inc. 3.0% 127.43 60.34 1/6/2012 Q1 Overweight Technology Hardware, Storage and PeripheraAAPL Internet Software and Services LNKD Technology Hardware, Storage and PeripheraHPQ LinkedIn Corporation 1.0% 249.50 192.62 2/21/2014 Q4 Overweight Hewlett-Packard Company 3.0% 31.87 28.34 1/3/2014 Q1 Overweight Communications Equipment PANW Palo Alto Networks, Inc. 1.0% 141.84 142.22 2/27/2015 Q4 Overweight IT Services XRX Xerox Corporation 1.0% 12.93 12.39 10/13/2014 Q2 Overweight IT Services VNTV Vantiv, Inc. 2.0% 38.48 31.95 8/8/2014 Q3 Overweight IT Services MA MasterCard Incorporated 3.0% 87.39 34.60 1/17/2012 Q1 Overweight Chemicals LYB LyondellBasell Industries N.V. 1.0% 90.95 34.50 10/28/2011 Q4 Overweight Chemicals EMN Eastman Chemical Co. 1.0% 69.48 77.03 11/29/2013 Q4 Equal-Weight Metals and Mining X United States Steel Corp. 1.0% 24.50 33.35 11/28/2014 Q1 Overweight Chemicals MON Monsanto Company 1.0% 117.04 79.02 4/5/2012 Q3 Overweight 49.70 50.59 11/28/2014 Q1 Overweight 64.20 45.44 1/3/2014 Q2 Equal-Weight Materials 3.2% Telecommunication Services Diversified Telecommunication Services 2.3% VZ Verizon Communications Inc. EIX Edison International Utilities Electric Utilities 4.0% 2.0% 2.0% 3.1% 1.0% 1.0% 100% 100% Source: Capital IQ, Thomson Reuters, Morgan Stanley Research Past performance is no guarantee of future results. Price performance does not take transaction costs into account. For companies in the portfolio, all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures. ++Rating for this company has been removed from consideration in this report because, under applicable law and/or Morgan Stanley policy, Morgan Stanley may be precluded from issuing such information with respect to this company at this time. NA = Not available NC = Not covered Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 61 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Disclosure Section The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary. For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA. For valuation methodology and risks associated with any price targets referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA. Analyst Certification The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Adam Parker. Unless otherwise stated, the individuals listed on the cover page of this report are research analysts. Global Research Conflict Management Policy Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. Important US Regulatory Disclosures on Subject Companies The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions. STOCK RATINGS Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Global Stock Ratings Distribution (as of March 31, 2015) For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equalweight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 62 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Disclosure Section (Cont.) Stock Rating Category Coverage Universe Investment Banking Clients (IBC) % of % of % of Rating Count Total Count Total IBC Category Overweight/Buy 1164 35% 331 43% 28% Equal-weight/Hold 1466 44% 353 46% 24% Not-Rated/Hold 100 3% 11 1% 11% Underweight/Sell 605 18% 80 10% 13% Total 3,335 775 Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Analyst Stock Ratings Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months. Analyst Industry Views Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below. In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index. Important Disclosures for Morgan Stanley Smith Barney LLC Customers Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures. Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 63 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Disclosure Section (Cont.) Other Important Disclosures Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix. Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix. Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments. The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons. With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel. Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management. Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 64 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy Disclosure Section (Cont.) To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives. Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Bank Morgan Stanley AG, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Bank Morgan Stanley AG, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Indonesia by PT Morgan Stanley Asia Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Conduct Authority, also disseminates Morgan Stanley Research in the UK. Private UK investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA. As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations. The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P. Morgan Stanley Research or portions of it may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 65 MORGAN STANLEY RESEARCH April 7, 2015 U.S. Equity Strategy The Americas Europe Japan Asia/Pacific 1585 Broadway New York, NY 10036-8293 United States +1 212 761 4000 20 Bank Street, Canary Wharf London E14 4AD United Kingdom +44 (0)20 7425 8000 1-9-7 Otemachi, Chiyoda-ku Tokyo 100-8104 Japan +81 (0) 3 6836 5000 1 Austin Road West Kowloon Hong Kong +852 2848 5200 ©2015 Morgan Stanley Adam S. Parker, Ph.D, (212) 761-1755, [email protected] 66